FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  PIMSTONE SIMON N.					2. Issuer Name <b>and</b> Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]						(Ch	5. Relationship of Reporting Person(s) (Check all applicable)  X Director 1			on(s) to Issi		
(Last) (First) (Middle) 200 - 3650 GILMORE WAY					3. Date of Earliest Transaction (Month/Day/Year) 06/28/2022							Officer below)	(give title		Other (s below)	pecify	
(Street) BURNA			V5G 4W8		4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	e) <mark>X</mark> Form f Form f					
(Oity)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)				2. Transa Date			3. Transaction	4. Secur	ities Acquired (A) or d Of (D) (Instr. 3, 4 and (A) or (D) Price		5. Amour Securitie Beneficia Owned F Reported Transact	5. Amount of Securities For Beneficially (D)		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		c	ransa ode (l	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date of Sec (Month/Day/Year) Underl Deriva		of Securit Underlyin Derivative	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				c	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$30.11	06/28/2022			A		18,000		(1)	06/27/2032	Common Shares	18,000	\$0.00	18,000		D	

## **Explanation of Responses:**

1. 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of

## Remarks:

/s/ Cassandra Robinson,

06/29/2022

Attorney-in-fact \*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.